The Journal of Practical Medicine >

2026 , Vol. 42 >Issue 10: 1745 - 1751

DOI: https://doi.org/10.3969/j.issn.1006-5725.2026.10.008

Chronic Disease Control

Association of PON1-Q192R gene polymorphism with severity of coronary artery lesions in patients with coronary heart disease

  • Yingxuan LI ,
  • Jun SHAO ,
  • Qian FENG ,
  • Tao CHEN ,
  • Jia LIU
Expand
  • 1.The Yangzhou School of Clinical Medicine of Dalian Medical University，Yangzhou 225001，Jiangsu，China
    2.College of Pharmacy，Dalian Medical University，Dalian 116044，Liaoning，China
    3.Heart and Vascular Center，Northern Jiangsu People's Hospital，Yangzhou 225001，Jiangsu，China
    4.Department of Pharmacy，Northern Jiangsu People's Hospital，Yangzhou 225001，Jiangsu，China

Received date: 2025-12-15

  Online published: 2026-05-27

Fold

Abstract

Objective To evaluate the association between the PON1-Q192R gene polymorphism and the severity of atherosclerotic lesions in coronary arteries among patients with coronary heart disease，and to analyze the influencing factors of the degree of coronary artery stenosis. Methods Patients diagnosed with coronary heart disease at Northern Jiangsu People's Hospital between January 2024 and December 2024 were enrolled in this study. The PON1-Q192R genotype was detected using PCR-based pyrosequencing. Compare the baseline data of patients with distinct genotypes. Patients were categorized into groups based on the severity of coronary atherosclerosis according to the Gensini score system：mild stenosis group（< 20 points），moderate stenosis group（20 - 39 points），and severe stenosis group（≥ 40 points）．The study examined the correlation between the PON1-Q192R gene polymorphism and Gensini scores，and compared the distribution characteristics of different genotypes across coronary artery stenosis groups in patients with coronary heart disease. Univariate and multivariate logistic regression analyses were employed to investigate the associated factors influencing the degree of coronary artery stenosis. Results The median Gensini score showed that patients with the AG and AA genotypes were significantly higher than those with the GG genotype（P < 0.05）．The proportion of patients with severe stenosis in the AG and AA genotypes was significantly higher than that in the GG genotype（P < 0.05）．Comparing the distribution of the PON1-Q192R G/A alleles across different degrees of coronary artery stenosis also showed statistically significant differences（P < 0.05）．Multivariate logistic regression analysis revealed that the AG genotype（OR = 1.973，95%CI：1.078 - 3.610，P = 0.027），AA genotype（OR = 3.127，95%CI：1.245 - 7.853，P = 0.015），hypertension（OR = 2.234，95%CI：1.233-4.046，P = 0.008），diabetes mellitus （OR = 2.043，95%CI：1.064 - 3.920，P = 0.032），and elevated LDL-C（OR = 1.608，95%CI：1.157 - 2.234，P = 0.005）were identified as risk factors for increased coronary artery stenosis severity. Conclusions The PON1-Q192R gene polymorphism is significantly associated with an increased risk of coronary artery stenosis severity in patients with coronary heart disease. The PON1-Q192R gene polymorphism can serve as an important indicator for predicting the severity of coronary artery stenosis in patients with coronary heart disease.

Key words： PON1-Q192R gene; genetic polymorphism; coronary heart disease; coronary artery stenosis severity; Gensini score

Cite this article

Yingxuan LI , Jun SHAO , Qian FENG , Tao CHEN , Jia LIU . Association of PON1-Q192R gene polymorphism with severity of coronary artery lesions in patients with coronary heart disease[J]. The Journal of Practical Medicine, 2026 , 42(10) : 1745 -1751 . DOI: 10.3969/j.issn.1006-5725.2026.10.008

References

[1] HEALTH T W C O T R O C， CHINA D I. 中国心血管健康与疾病报告2022概要［J］. 中国循环杂志， 2023， 38： 583-612. doi： 10.3969/j.issn.1000-3614.2023.06.001 .
[2] WU T T， ZHENG Y Y， MA X， et al. Mutated CYP17A1 promotes atherosclerosis and early-onset coronary artery disease［J］. Cell Commun Signal， 2023， 21（1）： 155. doi： 10.1186/s12964-023-01061-z .
[3] GAI M T， YAN S Q， WANG M Y， et al. Comparison of Gensini score and SYNTAX score for predicting in-stent restenosis in patients with coronary artery disease and drug-eluting stent implantation［J］. Sci Rep， 2025， 15（1）： 1077.doi： 10.1038/s41598-025-85191-z .
[4] HASBANI N R， LIGTHART S， BROWN M R， et al. American Heart Association's Life's Simple 7： Lifestyle Recommendations， Polygenic Risk， and Lifetime Risk of Coronary Heart Disease［J］. Circulation， 2022， 145（11）： 808-818.doi： 10.1161/circulationaha.121.053730 .
[5] DARAND M， SALEHI-ABARGOUEI A， VAHIDI MEHRJARDI M Y， et al. The association of the paraoxonase 1 Q192R polymorphism with coronary artery disease （CAD） and cardiometabolic risk factors in Iranian patients suspected of CAD［J］. Front Cardiovasc Med 2022，9： 1037940.doi：10.3389/fcvm.2022.1037940 .
[6] ASHIQ S， ASHIQ K. The Role of Paraoxonase 1 （PON1） Gene Polymorphisms in Coronary Artery Disease： A Systematic Review and Meta-Analysis［J］. Biochem Genet， 2021， 59（4）： 919-939.doi： 10.1007/s10528-021-10043-0 .
[7] YIGITTüRK O， TURGAY F， K?Z?LDA? S， et al. Do PON1-Q192R and PON1-L55M polymorphisms modify the effects of hypoxic training on paraoxonase and arylesterase activity？［J］. J Sport Health Sci， 2023， 12（2）： 266-274.doi： 10.1016/j.jshs.2020.11.004 .
[8] 中华医学会， 中华医学会杂志社， 中华医学会全科医学分会， 等. 稳定性冠心病基层诊疗指南（2020年）［J］. 中华全科医师杂志， 2021， 20（3）： 265-273. doi： 10.3760/cma.j.cn114798-20210120-00079 .
[9] RAMPIDIS G P， BENETOS G， BENZ D C， et al. A guide for Gensini Score calculation ［J］. Atherosclerosis， 2019， 287： 181-183.doi： 10.1016/j.atherosclerosis.2019.05.012 .
[10] 张晶， 刘佳， 陆康生， 等. CYP2C19、PON1-Q192R基因多态性与急性冠脉综合征患者行PCI术后抗血小板治疗药效的相关性研究［J］. 中国医院药学杂志， 2020， 40： 1544-1548. doi： 10.13286/j.1001-5213.2020.14.09 .
[11] 吴祯，税星，吴震，等.冠心病临界病变患者残余胆固醇/高密度脂蛋白胆固醇比值水平与冠脉CT血流储备分数的相关性［J］.中山大学学报（医学科学版）， 2024， 45（3）： 446-456. doi： 10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2024.0314 .
[12] FORREST I S， PETRAZZINI B O， DUFFY á， et al. Machine learning-based marker for coronary artery disease： Derivation and validation in two longitudinal cohorts ［J］. Lancet， 2023， 401（10372）： 215-225.doi： 10.1016/s0140-6736（22）02079-7 .
[13] CHARACH L， BLATT A， JONAS M， et al. Using the Gensini score to estimate severity of STEMI， NSTEMI， unstable angina， and anginal syndrome ［J］. Medicine （Baltimore）， 2021， 100（41）： e27331.doi： 10.1097/md.0000000000027331 .
[14] WYSOCKA A， CYBULSKI M， A P W， et al. Paraoxonase 1 Activity， Polymorphism and Atherosclerosis Risk Factors in Patients Undergoing Coronary Artery Surgery ［J］. J Clin Med， 2019， 8（4）.doi： 10.3390/jcm8040441 .
[15] SUN J， WANG L， YANG Q， et al. The Association of Paraoxonase-1 Polymorphism with Carotid Artery Stenosis among Elderly Chinese Population ［J］. Oxid Med Cell Longev， 2020， 2020： 3084120.doi： 10.1155/2020/3084120 .
[16] 吴和弟， 许丽娃， 吉家钗， 等. ALDH2基因多态性与老年2型糖尿病患者冠状动脉粥样硬化性心脏病易感性的关系［J］. 中国老年学杂志， 2022， 42（4）： 769-772. doi： 10.3969/j.issn.1005-9202.2022.04.001 .
[17] MUHEEB G， GUPTA M D， KUNAL S， et al. Novel lipid biomarkers and associated gene polymorphism in young ST-segment elevation myocardial infarction ［J］. Indian Heart J， 2023， 75（1）： 68-72.doi： 10.1016/j.ihj.2022.11.014 .
[18] JAKUBOWSKI H. The Molecular Bases of Anti-Oxidative and Anti-Inflammatory Properties of Paraoxonase 1 ［J］. Antioxidants （Basel）， 2024， 13（11）： 1292. doi： 10.3390/antiox13111292 .
[19] RACIS M， STANIS?AWSKA-SACHADYN A， SOBICZEWSKI W， et al. Association of Genes Related to Oxidative Stress with the Extent of Coronary Atherosclerosis ［J］. Life （Basel）， 2020， 10（9）：210.doi： 10.3390/life10090210 .
[20] BARANSKA M， RYCHLIK-SYCH M， DUDAREWICZ M， et al. Polymorphism rs662 （Q192R） of paraoxonase-1 and susceptibility to atherosclerosis of the coronary arteries ［J］. Arch Med Sci， 2024， 20（4）： 1328-1333.doi： 10.5114/aoms/192273 .
[21] NASREEN F J， BALASUBRAMANIAM G. Paraoxonase gene polymorphisms： Understanding the biochemical and genetic basis of coronary artery disease ［J］. J Taibah Univ Med Sci， 2023， 18（2）： 257-264.doi： 10.1016/j.jtumed.2022.10.001 .
[22] DUGGAN J P， PETERS A S， TRACHIOTIS G D， et al. Epidemiology of Coronary Artery Disease ［J］. Surg Clin North Am， 2022， 102（3）： 499-516.doi： 10.1016/j.suc.2022.01.007
[23] 赵岩，张耐，王霁雯，等. PCSK9抑制剂联合他汀类药物对重度颈内动脉狭窄患者CEA后LDL-C水平、认知功能及再狭窄的影响［J］. 中华神经医学杂志， 2026， 25（1）：77-83. doi：10.3760/cma.j.cn115354-20250902-00526 .
[24] 钱程昱， 王琳升， 熊兴江， 等. 血清低密度脂蛋白胆固醇、超敏C反应蛋白联合颈动脉超声参数诊断疑似冠心病患者的价值［J］. 实用医学杂志， 2025， 41（9）： 1401-1406. doi： 10.3969/j.issn.1006-5725.2025.09.019 .
[25] RAZA S T， ABBAS S， WANI I A， et al. Clinical implications of PON1 （rs662） and TNF-α （rs1799964） genes polymorphism in patients with coronary artery disease［J］. Egypt J Med Hum Genet， 2022， 23（1）：1-7.doi： 10.1186/s43042-022-00318-5 .
[26] MHAIMEED O， BURNEY Z A， SCHOTT S L， et al. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention： Lower for longer is better［J］. Am J Prev Cardiol， 2024， 18： 100649.doi： 10.1016/j.ajpc.2024.100649 .
[27] D'ANDRIA URSOLEO J， BALDETTI L， PIERI M， et al. Anti-Platelet Therapy with Cangrelor in Cardiogenic Shock Patients： A Systematic Review and Single-Arm Meta-Analysis［J］. Medicina （Kaunas）， 2024， 60（12）.doi： 10.3390/medicina60122092 .
Options
Outlines

/

〈 〉